Pseudomonas aeruginosa

May 18, 2016May 18, 2016

Potential New Drug Fights Bacteria and Viruses at Same Time, Researchers Say

Cystic Fibrosis, News

A potential new drug may help fight bacterial and viral infections at once, new research shows. With the immune response against viral infections making us susceptible to antibiotic resistant bacterial ... Read more

May 16, 2016May 16, 2016

Aradigm’s Candidates for NCFBE Featured at ATS 2016

Bronchiectasis, Cystic Fibrosis, News

The American Thoracic Society (ATS) is hosting the ATS 2016 International Conference through May 18 in San Francisco, Calif. Aradigm, an emerging pharmaceutical focused on drugs for the prevention and ... Read more

May 11, 2016May 11, 2016

Study Bolsters Support for Newborn Cystic Fibrosis Screenings in Quebec

Cystic Fibrosis, News

A new study led by a team from the Research Institute of the McGill University Health Centre (RI-MUHC) and Cystic Fibrosis Canada strongly supports the benefits of newborn screening programs ... Read more

April 28, 2016April 28, 2016

European Committee Releases Positive Opinion on Cystic Fibrosis Drug for Orphan Medicinal Product

Cystic Fibrosis, News

Canada-based biotech Arch Biopartners announced the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) has released a positive recommendation for the company’s treatment for infections linked to cystic fibrosis (CF). The ... Read more

April 19, 2016April 19, 2016

P. Aeruginosa in Cystic Fibrosis Can Be Eliminated with AmpliPhi’s Bacteriophage Candidate, According to Data

Cystic Fibrosis, News

AmpliPhi Biosciences Corporation, a biotech company dedicated to the development of novel bacteriophage-based antibacterial therapies, recently presented new clinical data regarding its proprietary investigational phage mix AB-PA01’s in vitro and ... Read more

April 12, 2016April 19, 2016

Quinsair Inhaled Therapy for Cystic Fibrosis Is Launched in Europe, Raptor Announces

Cystic Fibrosis, News

Raptor Pharmaceutical Corp. announced its first commercial sale of Quinsair, a levofloxacin inhalation solution, in Germany and Denmark. The European Union (EU) and Canada have already approved Quinsair for the management of ... Read more

April 6, 2016April 6, 2016

Arch Biopartners Licenses Drug Candidate to Treat CF Lung Infections

Cystic Fibrosis, News

Arch Biopartners, Inc., recently announced that it has entered an exclusive license agreement with the University of Cincinnati (UC) for commercial rights to UC’s AB569, a drug candidate for the ... Read more

March 22, 2016May 13, 2016

FDA Designation to Speed Testing of Inhaled Antibiotic, Levofloxacin, to Treat Lung Infections

Bronchiectasis, Cystic Fibrosis, News

Raptor Pharmaceutical Corp. announced that its proprietary inhaled levofloxacin, MP-376, has been given Qualified Infectious Disease Product (QIDP) designation by the U.S. Food and Drug Administration (FDA) to treat three specific indications: ... Read more

March 21, 2016May 13, 2016

Lung Infections in Cystic Fibrosis Found From Airborne Bacteria Triggering Fungal Growth

Cystic Fibrosis, News

According to new research, volatile compounds released by a bacterial pathogen called Pseudomonas aeruginosa can trigger the growth of a fungal pathogen often found in cystic fibrosis (CF) patients. This is ... Read more

March 8, 2016March 8, 2016

New Research into Cystic Fibrosis Lung Infections Could Pave Way to Better Treatments

Cystic Fibrosis, News

Recent research progress into how bacteria adapt and evolve in chronic lung infections in cystic fibrosis patients could lead to the development of improved treatment strategies, according to a new review ... Read more